The U.S. Supreme Court will hear arguments tomorrow over whether to limit access to the abortion pill mifepristone. The Biden administration is appealing a lower court’s decision that would roll back FDA actions in 2016 and 2021 to ease access to mifepristone. A ruling in favor of the plaintiffs could undercut federal regulatory authority over drug safety beyond just this medication.
The abortion opponents who are seeking to convince the court to limit access to the medication point to three studies by Gynuity Health Projects, a New York-based women’s health research group, to back up their arguments that it is unsafe despite its regulatory approval decades ago.
But the way the research has been prominently cited by the plaintiffs in their bid to limit how the pill is prescribed and distributed is bewildering to Dr. Beverly Winikoff, Gynuity’s president, given that the conclusions broadly support easier access to the medication. Read more.
|
